JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...

JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

Mr. Leibel's departure, as stated in the company's SEC filing, is not due to any disagreements or disputes with the company's operations or practices. He will continue to serve as an employee until ...

JMP Securities maintained its Market Perform rating on Apollo Global Management (NYSE:APO) shares without setting a new price ...

The killing U.S. bettors made this NFL season could nudge legal sports betting on this year’s Super Bowl toward $2 billion in regulated action.

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

Meta Platforms, Inc (NASDAQ:META) stock is trading higher after multiple firms raised their price forecasts on the stock ...

Even with its well-documented benefits, DoE is often underutilised, especially for solving specialised or constrained ...

AI is evolving rapidly with recent breakthroughs making it more accessible and efficient than ever. Smaller, cost-effective ...

We recently compiled a list of the 12 AI News Investors Probably Missed. In this article, we are going to take a look at ...

The web services and cybersecurity specialist's share price ended the day's trading up 10.7% amid the backdrop of a 0.8% gain ...